Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
” Operating expenses Operating expenses for the years ended December 31, 2025 and 2024 are summarized in the following table: Year ended December 31, 2025 2024 (in thousands, except percentages) Research and development $ 25,241 49 % $ 54,037 65 % General and administrative 15,893 30 % 22,108 27 % Change in fair value of contingent consideration (1,830) (4) % 2,625 3 % Restructuring costs 12,939 25 % 3,720 5 % Total operating expenses $ 52,243 100 % $ 82,490 100 % Research and development Research and development expenses consist primarily of personnel expenses, fees paid to clinical research organizations and contract manufacturers, consumables and materials, consulting, and other third-party expenses to support our clinical development activities, as well as a portion of stock-based compensation and general overhead costs. Research and development expenses decreased $28.8 million in 2025 compared to 2024 due primarily to our decision to cease all discovery efforts, halt preparations for a potential IM-PROVE III clinical trial, implement reductions in our workforce to streamline the organization, and to focus our efforts on advancing the clinical development of imdusiran and AB-101. A significant portion of our research and development expenses are not tracked by project, as they benefit multiple projects or our overall technology platform. General and administrative General and administrative expenses decreased $6.2 million in 2025 compared to 2024, due primarily to a decrease in employee compensation-related expenses and a decrease in litigation-related legal fees.
Read the full filing description · filed 23 Mar 2026
At a glance
- Sector
- Healthcare
Source: SEC filings. Information and analytics, not investment advice.